Hereditary angioedema: A current state-of-the-art review, VIII: Current status of emerging therapies

Annals of Allergy, Asthma and Immunology

Volumn 100, Issue 1 SUPPL. 2, 2008, Pages

  Bernstein, Jonathan A ^a,b  

^a UNIVERSITY OF CINCINNATI   (United States)

^b ML 563 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BERINERT P; BRADYKININ B2 RECEPTOR ANTAGONIST; CINRYZE; COMPLEMENT COMPONENT C1S INHIBITOR; DX 88; ICATIBANT; KALLIKREIN INHIBITOR; RHUCIN; UNCLASSIFIED DRUG;

ALLERGIC REACTION; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ANTIBODY RESPONSE; BLOOD PRESSURE; CHILL; CLINICAL TRIAL; CONFERENCE PAPER; DRUG HALF LIFE; ELECTROCARDIOGRAPHY; FEVER; HEADACHE; HEART RATE; HUMAN; HYPERSENSITIVITY REACTION; INJECTION SITE BURNING; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE REACTION; INJECTION SITE SWELLING; LABORATORY TEST; NONHUMAN; PHYSICAL EXAMINATION; PRIORITY JOURNAL; RELAPSE; SIDE EFFECT; URTICARIA; VITAL SIGN; WHEEZING;

EID: 38049076305     PISSN: 10811206     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1081-1206(10)60585-6     Document Type: Conference Paper

References (38)

1. Bowen B, Hawk JJ, Sibunka S, et al. A review of the reported defects in the human C1 esterase inhibitor gene producing hereditary angioedema including four new mutations. Clin Immunol. 2001;98:157-163.
2. Kalmar L, Bors A, Farkas H, et al. Mutation screening of the C1 inhibitor gene among Hungarian patients with hereditary angioedema. Hum Mutat. 2003;22:498.
3. Drouet C, Blanch A, Roche O. HAE: Mutation analysis of the C1INH gene. J Allergy Clin Immunol. 2004;114:S66-S74.
4. Agostoni A, Cicardi M. Hereditary and acquired C1-inhibitor deficiency: biological and clinical characteristics in 235 patients. Medicine. 1992;71:206-215.
5. Bork K, Staubach P, Eckardt AJ, et al. Symptoms, course, and complications of abdominal attacks in hereditary angioedema due to C1 inhibitor deficiency. Am J Gastroenterol. 2006;101:619-627.
6. Gompels MM, Lock RJ, Abinun M, et al. C1 inhibitor deficiency: consensus document. Clin Exp Immunol. 2005;139:379-394.
7. Bowen T, Cicardi M, Farkas H, et al. Canadian 2003 International Consensus Algorithm For the Diagnosis, Therapy, and Management of Hereditary Angioedema. J Allergy Clin Immunol. 2004;114:629-637.
8. De Serres J, Groner A, Lindner J. Safety and efficacy of pasteurized C1 inhibitor concentrate (Berinert P) in hereditary angioedema: a review. Transfus Apher Sci. 2003;29:247-254.
9. Bork K, Meng G, Staubach P, et al. Treatment with C1 inhibitor concentrate in abdominal pain attacks of patients with hereditary angioedema. Transfusion. 2005;45:1774-1784.
10. Martinez-Sauger I, Muller W, Pursun EA, et al. Pharmacokinetic parameters of C1 inhibitor concentrate in 40 patients with hereditary angioedema (HAE): a prospective study. Haemophilia. 2002;8:574.
11. Juers M, Groner A. Virus safety of current plasma-derived C1-INH: the Avenus Behring experience. J Allergy Clin Immunol. 2004;114:S96-S98.
12. Bork K, Barnstedt SE. Treatment of 193 episodes of laryngeal edema with C1 inhibitor concentrate in patients with hereditary angioedema. Arch Intern Med. 2001;161:714-718.
13. Bork K, Koch P. Episodes of severe dyspnea caused by snoring-induced recurrent edema of the soft palate in hereditary angioedema. J Am Acad Dermatol. 2001;45:968-969.
14. Bork K, Hardt J, Schicketanz KH, et al. Clinical studies of sudden upper airway obstruction in patients with hereditary angioedema due to C1 esterase inhibitor deficiency. Arch Intern Med. 2003;163:1229-1235.
15. Farkas H, Harmat G, Fust G, et al. Clinical management of hereditary angio-edema in children. Pediatr Allergy Immunol. 2002;13:153-161.
16. Bork K, Witzke G. Long-term prophylaxis with C1-inhibitor (C1 INH) concentrate in patients with recurrent angioedema caused by hereditary and acquired C1-inhibitor deficiency. J Allergy Clin Immunol. 1989;83:677-682.
17. Longhurst HJ, Bork K. Hereditary angioedema: causes, manifestations and treatment. Br J Hosp Med. 2006;67:654-657.
18. Terpstra FG, Kleijn M, Koenderman AH, et al. Viral safety of C1-inhibitor NF. Biologicals. 2007;35:173-181.
19. Tateishi J. Scrapie removal using planova virus removal filters. Biologicals. 2001;29:17-25.
20. Agostoni A, Aygoren-Pursun E, Binkley KE, et al. Hereditary and acquired angioedema: problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyond. J Allergy Clin Immunol. 2004;114:S51-S131.
21. van Doom MB, Burggraaf J, van Dam T, et al. A phase I study of recombinant human C1 inhibitor in symptomatic patients with hereditary angioedema. J Allergy Clin Immunol. 2005;116:876-883.
22. Choi G, Soeters MR, Farkas H, et al. Recombinant human C1-inhibitor in the treatment of acute angioedema attacks. Transfusion. 2007;47:1028-1032.
23. Nuijens JH, Verdonk R, Resink T, et al. Open-label studies of recombinant human C1 inhibitor in patients with acute attacks of hereditary angioedema. Paper presented at: 5th C1 Inhibitor Deficiency Workshop; 31 May 2007; Budapest.
24. Williams A, Baird LG. DX-88 and HAE: a developmental perspective. Transfus Apher Sci. 2003;29:255-258.
25. Lehmann A. Ecallantide (Dyax/Genzyme). Curr Opin Investig Drugs. 2006;7:282-290.
26. Levy JH, O'Donnell PS. The therapeutic potential of a kallikrein inhibitor for treating hereditary angioedema. Expert Opin Investig Drugs. 2006;15:1077-1090.
27. Cicardi M, Zingale L, Zanichelli A, Deliliers DL. Established and new treatments for hereditary angioedema: an update. Mol Immunol. 2007;44:3858-3861.
28. Caballero T, López-Serrano C. Anaphylactic reaction and antibodies to DX-88 (kallikrein inhibitor) in a patient with hereditary angioedema [letter]. J Allergy Clin Immunol. 2006;117:476-477.
29. Beck TR, Baird LG. Anaphylactic reaction and antibodies to DX-88 (kallikrein inhibitor) in a patient with hereditary angioedema [response]. J Allergy Clin Immunol. 2006;117:477.
30. Icatibant. HOE 140, JE 049, JE049, 9,10. Drugs. 2005;6:239-244.
31. Bhoola KD, Figueroa CD, and Worthy K. Bioregulation of kinins: kallikreins, kininogens, and kininases. Pharmacol Rev. 1992;44:1-80.
32. Dray A, Perkins M. Bradykinin and inflammatory pain. Trends Neurosci. 1993;16:99-104.
33. Nussberger J, Cugno M, Cicardi M. Bradykinin-mediated angioedema. N Engl J Med. 2002;347:621-622.
34. Cugno M, Nussberger J, Cicardi M, Agostoni A. Bradykinin and the pathophysiology of angioedema. Int Immunopharmacol. 2003;3:311-317.
35. Han ED, MacFarlane RC, Mulligan AN, Scafidi J, Davis AE III. Increased vascular permeability in C1 inhibitor-deficient mice mediated by the bradykinin type 2 receptor. J Clin Invest. 2002;109:1057-1063.
36. Davis AE III. Mechanism of angioedema in first complement component inhibitor deficiency. Immunol Allergy Clin North Am. 2006;26:633-651.
37. Cockcroft JR, Chowienczyk PJ, Brett SE, Bender N, Ritter JM. Inhibition of bradykinin-induced vasodilation in human forearm vasculature by Icatibant, a potent B2-receptor antagonist. Br J Clin Pharmacol. 1994;38:317-321.
38. Bork K, Frank J, Grundt B, Schlattmann P, Nussberger J, Kreuz W. Treatment of acute edema attacks in hereditary angioedema with a bradykinin receptor-2 antagonist (Icatibant). J Allergy Clin Immunol. 2007;119:1497-1503.